Researchers from Harvard Medical School and the Icahn School of Medicine at Mount Sinai found two rare, recurrent patterns of mutation in the post-mortem brain tissue of individuals with schizophrenia that could reflect prenatal mutational processes.
The potential of psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin in treating various neuropsychiatric disorders has received increased attention in recent times. These compounds are believed to exert their effects through the serotonin 5-HT2A receptor.
Archetype Therapeutics Inc. has discovered compounds for the treatment of early-stage lung adenocarcinoma by screening billions of compounds from the Enamine REAL Space chemical library and other libraries.
Researchers from the Icahn School of Medicine at Mount Sinai and affiliated organizations presented the discovery and preclinical characterization of MS-8535, a novel spindlin-1 (SPIN1) inhibitor being developed as chemical tool anticancer agent.
Scientists at Mount Sinai School of Medicine and U.S. Department of Veterans Affairs have synthesized mothers against decapentaplegic homolog 3 (SMAD3) inhibitors reported to be useful for the treatment of renal, hepatic and pulmonary fibrosis.
JAK1 signaling promotes skin inflammation and is a major therapeutic target for atopic dermatitis-related itching. But in a study appearing in the Jan. 4, 2024, print issue of Cell after earlier publication online, researchers at the Icahn School of Medicine at Mount Sinai, led by dermatologist Brian Kim, found that intrinsic JAK1 signaling in sensory neurons had an immunoprotective effect in the lung. The findings suggest a more precise and personalized approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
Despite continual investment in research focused on high-grade serous ovarian cancer (HGSOC), the 5-year survival rate of ∼30% for most patients has remained unchanged for decades. While ≤20% of HGSOC patients present with treatment-refractory disease, therapeutic strategies have not changed outcomes for these patients in 40 years.
In recent work, researchers from Mount Sinai School of Medicine applied a drug repurposing approach to identify candidates that could target inflammation in atherosclerosis.
Researchers at Mount Sinai Hospital have demonstrated that a machine learning-based model enables medical institutions to predict mortality risk for individual cardiac surgery patients.
